For patients with MDD, individuals who received GeneSight had total costs of $18,741 compared to $24,971 in TAU arm representing total cost savings of $6,050.

“From the perspective of managed care decision makers, as our results indicate, the use of CPGx offers clinicians and their patients the benefit of more precise selection of psychotropic drugs while offering cost savings to the health plan. Moreover, coverage of CPGx may yield material PMPM savings associated with spending on anxiety, depression and bipolar disorder and marginal PMPM savings associated with overall spending on psychiatric disorders. Since the test cost is a one-time investment, average savings are expected to increase as the duration is extended over the life cycle of psychiatric treatment.”

Benitez J, et al. Use of combinatorial pharmacogenomic guidance in treating psychiatric disorders: financial impact on a health plan. Per Med 2018 Nov; 15(6):481-94.

Learn More View Article

Healthcare utilization cost higher for patients using problematic medications compared to patients using better tolerated medications.

“Subjects whose medication regimen included a medication identified by the gene-based interpretive report as most problematic for that patient and are in the ‘red bin’ (medication status of ‘use with caution and frequent monitoring’), had 69% more total health care visits, 67% more general medical visits, greater than three-fold more medical absence days, and greater than four-fold more disability claims than subjects taking drugs categorized by the report as in the green bin (‘use as directed’) or yellow bin (‘use with caution’).”

Winner JG, et al. Psychiatric pharmacogenomics predicts health resource utilization of outpatients with anxiety and depression. Transl Psychiatry 2013 Mar 19; 3:e242.

Learn More View Article

79% of clinicians made decisions congruent with report recommendations, reducing overall post-test medication costs and improving adherence.

“Patients who received pharmacogenomic (PGx) testing saved $1035.60 in total medication costs (both CNS and non-CNS medications) over 1 year compared to the non-tested standard of care cohort (p = 0.007). PGx testing improved adherence compared to standard of care (ΔPDCCPGx = 0.11 vs ΔPDCTAU = −0.01; p < 0.0001). Pharmacy cost savings averaged $2774.53 for patients who were changed to a combinatorial pharmacogenomic (CPGx) congruent medication regimen, compared to those who were not (p < 0.0001).”

Winner JG, et al. Combinatorial pharmacogenomic guidance for psychiatric medications reduces overall pharmacy costs in a 1 year prospective evaluation. Curr Med Res Opin 2015 Sep; 31(9):1633-43.

Learn More View Article

CPGx improved treatment response rate by 70%, resulting in patient cost savings over lifetime.

“CPGx improved the treatment response rate by 70% (1.7 times as high as that with TAU), increasing QALYs by 0.316 years. With these health benefits, CPGx is expected to save $3711 in direct medical costs per patient and $2553 in work productivity costs per patient over the lifetime. The cost-effectiveness of CPGx testing was robust over a wide range of variation in the input parameters, including the scenario when testing efficacy was set to its lower limit.”

Hornberger J, et al. Cost-effectiveness of combinatorial pharmacogenomic testing for treatment resistant MDD patients. The American Journal of Managed Care 2015 August; 21(6):e357-65.

Learn More View Article